6-KThe Wire
HUTCHMED (China) Ltd files 6-K
Filed May 21, 2026 · 1mo ago · Accession 0001648257-26-000033
Plain English
HUTCHMED (CHINA) LIMITED announced the NMPA approval for ELUNATE® (Fruquintinib) in combination with TYVYT® (Sintilimab Injection) for the treatment of patients with locally advanced or metastatic renal cell carcinoma.
Filing details
- Company
- HUTCHMED (China) Ltd
- Ticker
- HCM
- CIK
- 1648257
- Form type
- 6-K
- Filing date
- May 21, 2026
- Report date
- May 21, 2026
- Document
- hcm-20260521x6k.htm
- Size
- 59 KB